LYRA Stock Lyra Therapeutics (LYRA, $0.09) RSI Indicator left the oversold zone on April 22, 2025

GET DAILY SIGNALS

Get AI intraday signals

LYRA - Lyra Therapeutics

RSI signal

View

Odds of UP Trend

Price: $0.093

Daily change: +$0.0057 (+6.53%)

Daily volume: 1.5M

Capitalization: $6.1M

Industry: Biotechnology

LYRA in -5.23% downward trend, falling for three consecutive days on May 19, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where LYRA declined for three days, in of 325 cases, the price declined further within the following month. The odds of a continued downward trend are .

Technical Analysis (Indicators)

Bearish Trend Analysis

LYRA broke above its upper Bollinger Band on April 29, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LYRA's RSI Oscillator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Momentum Indicator moved above the 0 level on May 15, 2025. You may want to consider a long position or call options on LYRA as a result. In of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for LYRA just turned positive on April 22, 2025. Looking at past instances where LYRA's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where LYRA advanced for three days, in of 237 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 136 cases where LYRA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.829) is normal, around the industry mean (16.212). P/E Ratio (0.000) is within average values for comparable stocks, (60.468). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.177). Dividend Yield (0.000) settles around the average of (0.023) among similar stocks. P/S Ratio (5.914) is also within normal values, averaging (281.268).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. LYRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LYRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.